BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers Med 2017;7:E1. [PMID: 28125057 DOI: 10.3390/jpm7010001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1. J Pers Med 2018;8:E17. [PMID: 29735910 DOI: 10.3390/jpm8020017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
2 Johnson D, Hughes D, Pirmohamed M, Jorgensen A. Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. J Pers Med 2019;9:E42. [PMID: 31480618 DOI: 10.3390/jpm9030042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, Wang C. An overview of polymeric nanomicelles in clinical trials and on the market. Chinese Chemical Letters 2021;32:243-57. [DOI: 10.1016/j.cclet.2020.11.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
4 Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J Pers Med 2017;7:E19. [PMID: 29207572 DOI: 10.3390/jpm7040019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Graziadio S, Winter A, Lendrem BC, Suklan J, Jones WS, Urwin SG, O'Leary RA, Dickinson R, Halstead A, Kurowska K, Green K, Sims A, Simpson AJ, Power HM, Allen AJ. How to Ease the Pain of Taking a Diagnostic Point of Care Test to the Market: A Framework for Evidence Development. Micromachines (Basel) 2020;11:E291. [PMID: 32164393 DOI: 10.3390/mi11030291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther 2021;228:107932. [PMID: 34174272 DOI: 10.1016/j.pharmthera.2021.107932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bielekova B, Pranzatelli MR. Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping. Semin Pediatr Neurol 2017;24:229-39. [PMID: 29103430 DOI: 10.1016/j.spen.2017.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
8 Lévy V. Of some innovations in clinical trial design in hematology and oncology. Therapie 2021:S0040-5957(21)00245-6. [PMID: 34922739 DOI: 10.1016/j.therap.2021.10.011] [Reference Citation Analysis]
9 Wilkinson J, Brison DR, Duffy JMN, Farquhar CM, Lensen S, Mastenbroek S, van Wely M, Vail A. Don’t abandon RCTs in IVF. We don’t even understand them. Human Reproduction 2019;34:2093-8. [DOI: 10.1093/humrep/dez199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
10 López-Muñoz E, Mejía-Terrazas GE. Epigenetics and postsurgical pain: A scoping review. Pain Med 2021:pnab234. [PMID: 34314508 DOI: 10.1093/pm/pnab234] [Reference Citation Analysis]
11 Krause M, Alsner J, Linge A, Bütof R, Löck S, Bristow R. Specific requirements for translation of biological research into clinical radiation oncology. Mol Oncol 2020;14:1569-76. [PMID: 32175659 DOI: 10.1002/1878-0261.12671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wilkinson J, Arnold KF, Murray EJ, van Smeden M, Carr K, Sippy R, de Kamps M, Beam A, Konigorski S, Lippert C, Gilthorpe MS, Tennant PWG. Time to reality check the promises of machine learning-powered precision medicine. Lancet Digit Health 2020;2:e677-80. [PMID: 33328030 DOI: 10.1016/S2589-7500(20)30200-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 12.5] [Reference Citation Analysis]
13 Wang Y, Carter BZ, Li Z, Huang X. Application of machine learning methods in clinical trials for precision medicine. JAMIA Open 2022;5:ooab107. [DOI: 10.1093/jamiaopen/ooab107] [Reference Citation Analysis]
14 Lee KM, Wason J. Design of experiments for a confirmatory trial of precision medicine. J Stat Plan Inference 2019;199:179-87. [PMID: 31007363 DOI: 10.1016/j.jspi.2018.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
16 Antoniou M, Kolamunnage-Dona R, Wason J, Bathia R, Billingham C, Bliss JM, Brown LC, Gillman A, Paul J, Jorgensen AL. Biomarker-guided trials: Challenges in practice. Contemp Clin Trials Commun 2019;16:100493. [PMID: 31788574 DOI: 10.1016/j.conctc.2019.100493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
17 Rocca A, Kholodenko BN. Can Systems Biology Advance Clinical Precision Oncology? Cancers (Basel) 2021;13:6312. [PMID: 34944932 DOI: 10.3390/cancers13246312] [Reference Citation Analysis]
18 Superchi C, Brion Bouvier F, Gerardi C, Carmona M, San Miguel L, Sánchez-Gómez LM, Imaz-Iglesia I, Garcia P, Demotes J, Banzi R, Porcher R; PERMIT Group. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open 2022;12:e052926. [PMID: 35523482 DOI: 10.1136/bmjopen-2021-052926] [Reference Citation Analysis]
19 Italiano A, Dinart D, Soubeyran I, Bellera C, Espérou H, Delmas C, Mercier N, Albert S, Poignie L, Boland A, Bourdon A, Geneste D, Cavaille Q, Laizet Y, Khalifa E, Auzanneau C, Squiban B, Truffaux N, Olaso R, Gerber Z, Wallet C, Bénard A, Blay JY, Laurent-Puig P, Deleuze JF, Lucchesi C, Mathoulin-Pelissier S; MULTISARC study group. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. BMC Cancer 2021;21:1180. [PMID: 34740331 DOI: 10.1186/s12885-021-08878-2] [Reference Citation Analysis]
20 Kypriotakis G, Cinciripini PM, Versace F. Modeling neuroaffective biomarkers of drug addiction: A Bayesian nonparametric approach using dirichlet process mixtures. J Neurosci Methods 2020;341:108753. [PMID: 32428623 DOI: 10.1016/j.jneumeth.2020.108753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, Siegel R, Fink M, Ahmed S, Millholland J, Schuhmacher A, Hinder M, Piali L, Roth A. Translational precision medicine: an industry perspective. J Transl Med 2021;19:245. [PMID: 34090480 DOI: 10.1186/s12967-021-02910-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]